Peripheral Arterial Disease clinical trials

Explore recruiting peripheral arterial disease clinical trials.

Recruiting peripheral arterial disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Peripheral Arterial Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease (GENPAD)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase IIa Open Label, Dose-Finding, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients with Peripheral Arterial Disease (PAD). CLAUDIA Trial

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Low dose ColchicinE in pAtients with peripheral artery DiseasE to address residual vascular Risk: A randomized trial- LEADER PAD

Italy, Belgium, Netherlands, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

J2A-MC-GZPR: A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial

Slovakia, Poland, France, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

VIRTUOSE: Efficiency of sildenafil on the absolute claudication distance of peripheral arterial disease patients with intermittent claudication. A phase III, National, Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled trial.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease.

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Peripheral Arterial Disease trials by city

Peripheral Arterial Disease in Toronto Peripheral Arterial Disease in Vancouver Peripheral Arterial Disease in Montreal Peripheral Arterial Disease in Calgary Peripheral Arterial Disease in Edmonton Peripheral Arterial Disease in Ottawa Peripheral Arterial Disease in Winnipeg Peripheral Arterial Disease in Quebec City Peripheral Arterial Disease in Hamilton Peripheral Arterial Disease in Kitchener Peripheral Arterial Disease in London Peripheral Arterial Disease in Halifax Peripheral Arterial Disease in New York Peripheral Arterial Disease in Los Angeles Peripheral Arterial Disease in Chicago Peripheral Arterial Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease